Life sciences investor Sofinnova Ventures is raising fund number 10 in what, as FierceBiotech notes, appears to be its largest fund to date. A previous fund, dating back to 2014, raised $500 million.
The investment firm did not immediately respond to a request for comment about Sofinnova Venture Partners X fund.
The company’s strategy of investing in late-stage private companies has found some receptive buyers for those businesses, demonstrated by acquisitions of its portfolio companies from the likes of Teva, Shire and Pfizer.
Image: http://medcitynews.com
